Hepatitis C Virus Treatment Guidelines

For recommended and alternative regimens for specific patient populations (eg, treatment-experienced patients previously treated with regimens other than PEG-IFN/ribavirin, decompensated cirrhosis, HIV/HCV co-infection, renal impairment, etc), refer to the full guideline or drug manufacturer’s labeling.

¹ Patients with no baseline NS5A RASs for elbasvir detected. Includes G1a substitutions at amino acid positions 28, 30, 31, or 93 known to confer antiviral resistance.

² An 8-week duration is recommended for treatment-naïve patients without cirrhosis who are HIV uninfected, and whose HCV RNA level is <6 million IU/ml.

³ Baseline NS5A RAS Y93H testing for velpatasvir is recommended. If present, ribavirin should be added to the regimen, or change regimen to Vosevi.

⁴ 12 weeks is recommended for patients who experience virologic relapse after PEG-IFN/ribavirin therapy. If the type of prior treatment failure (relapse vs breakthrough/nonresponse) is unknown, another recommended regimen should be used.

⁵ Duration of 12 weeks is recommended for HIV/HCV co-infection.

⁶ Consider an 8-week regimen in patients with genotype 1b and mild fibrosis.

⁷ Consider an 8-week regimen in patients with favorable baseline characteristics (eg, no cirrhosis, HCV RNA <6 million IU/mL, absence of genotype 4r.

⁸ Not recommended for genotype 6e if subtype is known.

AASLD-IDSA. HCV Guidance: Recommendations for testing, managing, and treating hepatitis C. http://www.hcvguidelines.org. Accessed October 20, 2020.

(Rev. 10/2020)